Steven Burke
Vermögen: 531 735 $ am 30.09.2026
Vermögen: 531 735 $ am 30.09.2026
Dr. Steven K.
Burke, MD, is a Chief Medical, Research & Development Officer at Akebia Therapeutics, Inc. He is on the Board of Directors at SCYNEXIS, Inc., AbFero Pharmaceuticals, Inc. and LeukoSight, Inc. Dr. Burke was previously employed as a Chief Medical Officer & Senior Vice President by Proteon Therapeutics, Inc., a Senior Vice President-Medical & Regulatory Affairs by Genzyme Corp., a Medical Director & VP-Clinical Research by GelTex Pharmaceuticals, Inc., an Associate Director-Clinical Research by Glaxo, Inc., and a Chief Medical Officer by Protara Therapeutics, Inc. He received his undergraduate degree from Harvard College and a doctorate degree from Weill Cornell Medical College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 547’098 ( 0.2% ) | 503 330 $ | 30.09.2026 | |
SCYNEXIS, INC. 0.06% | 18.09.2026 | 5’750 ( 0.06% ) | 28 405 $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.06.2019 |
| SCYNEXIS, INC. | Direktor/Vorstandsmitglied | 18.09.2026 |
LeukoSight, Inc.
LeukoSight, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics to treat autoimmune and inflammatory diseases | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| PROTARA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops non-absorbed, polymer-based pharmaceuticals | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 |
AbFero Pharmaceuticals, Inc.
AbFero Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral iron chelators for the treatment of diseases of iron overload | Gründer | - |
| PROTARA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Glaxo, Inc. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops non-absorbed, polymer-based pharmaceuticals | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Proteon Therapeutics, Inc.
Proteon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops pharmaceuticals products for patients with renal and vascular disease | Health Technology |
SCYNEXIS, Inc.
SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Glaxo, Inc. | |
LeukoSight, Inc.
LeukoSight, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics to treat autoimmune and inflammatory diseases | Health Technology |
Weill Cornell Medical College
Weill Cornell Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AbFero Pharmaceuticals, Inc.
AbFero Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral iron chelators for the treatment of diseases of iron overload | Health Technology |
Protara Therapeutics, Inc.
Protara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen